Company intelligence / Profile preview

Intract Pharma

London, United Kingdomintractpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Intract Pharma specializes in oral drug delivery technologies for targeted release within the gastrointestinal tract. Their proprietary platforms enable oral administration of biopharmaceuticals that would otherwise require injection. One clinic-stage product using their technology has completed Phase III trials with market entry anticipated as of 2019. The company continues to develop additional programs focused on chronic inflammatory and autoimmune conditions

Therapeutic areas: GastroenterologyImmunology
Modalities: Oral delivery of biopharmaceuticals (including monoclonal antibodies and complex proteins)
Industry: Biotech

Drug pipeline

1 asset

infliximab

Pre-clinical

Indications: Crohn's disease, Ulcerative colitis, Rheumatoid arthritis, Plaque psoriasis

Beyond the preview

Go deeper on Intract Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intract Pharma.

Explore the full profile